Asset Details
Do you wish to reserve the book?
Neurofilament light chain as a biomarker in neurological disorders
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Neurofilament light chain as a biomarker in neurological disorders
Do you wish to request the book?
Neurofilament light chain as a biomarker in neurological disorders
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Neurofilament light chain as a biomarker in neurological disorders
2019
Overview
In the management of neurological diseases, the identification and quantification of axonal damage could allow for the improvement of diagnostic accuracy and prognostic assessment. Neurofilament light chain (NfL) is a neuronal cytoplasmic protein highly expressed in large calibre myelinated axons. Its levels increase in cerebrospinal fluid (CSF) and blood proportionally to the degree of axonal damage in a variety of neurological disorders, including inflammatory, neurodegenerative, traumatic and cerebrovascular diseases. New immunoassays able to detect biomarkers at ultralow levels have allowed for the measurement of NfL in blood, thus making it possible to easily and repeatedly measure NfL for monitoring diseases’ courses. Evidence that both CSF and blood NfL may serve as diagnostic, prognostic and monitoring biomarkers in neurological diseases is progressively increasing, and NfL is one of the most promising biomarkers to be used in clinical and research setting in the next future. Here we review the most important results on CSF and blood NfL and we discuss its potential applications and future directions.
Publisher
BMJ Publishing Group Ltd,BMJ Publishing Group LTD
Subject
/ Amyotrophic lateral sclerosis
/ Biomarkers - cerebrospinal fluid
/ cerebrospinal-fluid biomarkers
/ csf
/ Dementia
/ disease
/ Humans
/ Light
/ marker
/ Nervous System Diseases - blood
/ Nervous System Diseases - cerebrospinal fluid
/ Nervous System Diseases - diagnosis
/ Neurofilament Proteins - blood
/ Neurofilament Proteins - cerebrospinal fluid
/ protein
/ Surgery
